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CC BY-NC-ND license (http://creativeA systematic assessment of literature was done to estimate the impact of pruritus on health-
related quality of life among patients with cholestatic liver disease (CLD). All the articles were
reviewed manually for study design, population, outcomes, and study quality. A qualitative
approach was used to analyze and extract data from included studies. A total of eight studies
were retrieved, of which one was a cohort study and the other seven were cross-sectional
studies. Overall, it appears that the incidence of pruritus was a common complication reported
by most of the studies. Among patients with CLD incidence of pruritus was 29%. Pruritus was
found to have a substantial impact on patients’ health-related quality of life. Greater
health-related quality of life impairment was observed with increased severity of pruritus. Pru-
ritus was found to have a significant association (p < 0.05) in quality-of-life instrument do-
mains such as role limitationephysical, role limitationeemotional, bodily pain, vitality,
energy, and physical mobility. Evidence suggests that pruritus has a substantial impact on
health-related quality of life among patients with CLD. More research is required to support
the evidence.
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Pruritus is defined as an irritating and unpleasant sensation
that provokes the desire to scratch.1 Despite being a com-
mon symptom in many dermatological conditions, pruritus
can also be caused by systemic diseases such as cancer,
chronic renal failure, cholestasis, hyperthyroidism, dia-
betes mellitus, and iron-deficiency anemia (hematologic).1
Pruritus is a common symptom in patients with cholestaticby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
Table 1 Number of records found in each database.
Databases Number of records
PubMed 55
CINAHL plus 13
Cochrane Library 1
Medline 93
Embase 203
Scopus 268
690 X.Y. Jin, T.M. Khanliver disease (CLD) such as primary biliary cirrhosis (PBC)
and primary sclerosing cholangitis (PSC).2 Among the pa-
tients with liver diseases, 80e100% with cholestasis suffer
from chronic pruritus.3 Often pruritus is refractory and it
has shown substantial negative impact on health-related
quality of life (HRQL) by impairing both physical and
mental health. Pruritus can also be the sole indication for
orthotopic liver transplantation even though hepatic
decompensation is absent.
Quality of life (QOL) is a patient-reported measure
comprised of physical well-being, emotional well-being,
and social functioning. It reflects on the perception of an
individual regarding their health status. HRQL focuses on
the effects of a disease on every dimension of an in-
dividual’s life including physical, social, psychological,
emotional, and cognitive functioning.4 HRQL assessment
has become a key component in the evaluation of thera-
peutic intervention. Patients are more attentive to
morbidity and quality than longevity, especially those with
chronic illnesses. The goal of intervention is also mainly
centralized in maintaining community-living and symptom-
free patients.5
There are only limited data available regarding the
impact of pruritus on HRQL among patients with CLD. No
study has ever specifically assessed the relationship be-
tween pruritus and HRQL among these patients. Most of the
studies focused only on the impact of general symptoms,
such as fatigue and muscle cramps that are closely associ-
ated with CLD, on HRQL. Besides, previous findings on the
incidence and severity of pruritus in CLD are scarce. Pru-
ritus only receives minor attention from both patients and
doctors because it is often not considered to be a condition
worth assessing or treating.6 Pruritus is also not visible and
it is hard to identify the intensity of pruritus based on
symptoms. Thus, a systematic review is appealing to pro-
vide information regarding the impact of pruritus on quality
of life in order to fulfill the gap of knowledge in the com-
munity. In addition, this review regarding the epidemiology
of pruritus as a whole may also reveal a massive burden of
disease in the community.
In this systematic review, we reviewed both randomized
controlled trials and observational studies that assessed
QOL among patients suffering from liver disease induced
pruritus, particularly in CLD (PBC and PSC). Patient HRQL
was compared with those of a healthy population in order
to indicate the extent of impairment in HRQL.
Method
Literature search
To identify studies that evaluate the HRQL among patients
suffering from CLD induced pruritus, online journal articles
indexed were searched in the following databases PubMed,
CINAHL plus, Cochrane library, Medline, Embase, and Sco-
pus. The search was done from inception of databases till
31st August 2015. Research articles published in English
language were considered for further assessment. Titles
and abstracts were searched by using OR and AND Boolean
to combine free texts and MeSH terms including “quality of
life” or “life quality” and pruritus or pruritic or pruritis oritch* and cholestasis or cholestases or cholangitis or chol-
angitides or cirrhosis or cirrhosis (Table 1). The references
of retrieved articles were reviewed for other articles that
may be relevant to the research aim in order to comple-
ment the search. All titles and abstracts were screened for
relevance and full texts were obtained if appropriate.
Study selection
An article was included in our systematic review if it met
each of the following criteria: (1) the study assesses the
QOL among patients with CLDs, including PBC or PSC; (2)
impact of pruritus or itch on QOL must be assessed and
sufficient data must be provided in the study; (3) the study
was reported in an original article; and (4) the study design
was a randomized controlled trial, cross-sectional study, or
cohort study.
Data extraction and quality assessment
Abstracts with relevant content were selected for full texts
review. Data were extracted using standardized data
collection forms onto a Microsoft Excel spreadsheet. The
form included title, year of publication, journal title,
objective, study design, study population, number of re-
spondents, method, summary of findings, and study limi-
tations. The methodological quality of each article selected
was assessed by using quality assessment tool devised by
National Institutes of Health.7 This is a standard quality
checklist that specifically tailored to assess the quality of
observational cohort and cross-sectional studies.7 For each
item, a similar grading scale was applied (yesZUZ 1 and
no Z ✗ Z 0). If the criteria were not applicable to the
study, NA is indicated and the item rated as 1. If the criteria
were not reported in the study, NR was indicated and the
item rated as 0. All areas were summed and the quality of
the included studies were rated as good (total > 10), fair
(5 < total < 11), or poor (total < 6).Results
Study selection and characteristics
From the literature search of electronic database, 633
studies were identified. Two additional studies were found
from other sources. After removal of duplications, 217 ar-
ticles remained. There were 94 full-text articles selected
based on title and abstract, following by assessment for
QOL in cholestatic liver disease-induced pruritus 691eligibility. Only eight studies were included in our system-
atic review. A flow diagram is presented in Figure 1.
Included studies were published over a period of
17 years, from 1999 to 2015. Of the studies that met our
research criteria, seven were cross-sectional study and one
was a cohort study. Our review included a total of 1548
participants who suffered from PBC or PSC or both.2,5,8e13
Of the eight eligible studies, one study investigated the
QOL before and after liver transplantation among patients
with CLD.8 Another study assessed the impact of fatigue in
QOL among patients with PBC.9 Although these two studies
had titles that appear irrelevant to our research aim, data
regarding the impact of pruritus on QOL were reported. The
remaining six studies were included as they investigated
the impact of pruritus on QOL among patients with CLD,
which perfectly fulfilled our inclusion criteria.2,5,10e13 The
study details are shown in Table 2.HRQL instruments
In our systematic review, there were six different HRQL
instruments were used in the eight studies (Table 3). Among
them, two were generic, two were PBC-specific, and two
were liver disease-specific. The most frequently used HRQL
tools were SF-36. Five out of the eight studies used SF-36 to
measure HRQL.2,5,10,11,13 Two studies used Chronic Liver
Disease Questionnaire (CLDQ), two used Nottingham Health
Profile Questionnaire (NHPQ), two used National Institute ofRecords identified through 
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Figure 1 PRISMA flow diagDiabetes and Digestive and Kidney DiseaseseQuality of Life:
Adults, and one study used both PBC-40 and PBC-27 to
measure HRQL among the patients.2,5,8e12 Three studies
used both generic and disease-specific HRQL tools to assess
HRQL.2,10,11 All the HRQL assessment tools are reliable and
validated for assessing HRQL in patients with CLD except for
PBC-40 and PBC-27.14e20 Raszeja et al11 was the first study
to evaluate the reliability of PBC-40 and PBC-27 in assessing
HRQL among PSC patients. This study concluded that both
questionnaires could be of future use for HRQL assessment
in PSC patients. Nevertheless, they must be used with
caution by taking into consideration of different charac-
teristics between PSC and PBC.11 Details of HRQL in-
struments are shown in Table 3.HRQL among cholestatic patients
Six of the studies reported greater HRQL impairment in
patients with CLD compared to healthy controls.2,5,8,10e12
Comparison of HRQL between patients with CLD and a
normal population was not reported by Stanca et al9 or
Gotthardt et al.13 This was because the main focus of
Stanca et al9 was on the correlation between liver disease
symptoms and QOL, and Gotthardt et al13 identifies the
factors associated with QOL in patients with PSC. Gotthardt
et al stated that comparable high values for SF-36 indi-
cating good HRQL in PSC patients.13 However, the validity
of this statement is questionable as there is no comparisonAdditional records identified through 
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Table 2 Characteristics of included studies.
First
author,
yearref
Objective Study
design
Study population HRQL
measures
(method)
Summary
of findings
Study
limitationsIntervention
group
Comparison
group
Gross,
19998
Describe the
health
status and
QOL in
patients with
CLD before
and after
liver
transplantation.
Cross-
sectional
study
Patients who received liver
transplantations
for PBC or PSC between April 1990 and
January 1995 at Baylor University Medical
Center or Mayo Clinic.
nZ 157 (95 Mayo; 62 BUMC)
NIDDK
LTD-QOL
Comparison
of QOL was
made in
between
patients with
PBC or PSC
before and
1 y after
liver
transplantation.
No significant differences
of QOL between patients
with PBC and PSC.
The 3 most bothersome
symptoms before LT were
fatigue, sleeplessness
and skin itching. Pruritus
showed the greatest
improvement after LT,
from moderate distress
to almost not at all.
History of encephalopathy
was found more common in
nonrespondent which may impair
the QOL of patients. In addition,
in depth information on health
status and QOL is not obtainable.
Moreover, the bilirubin level
was significantly higher, this
may have adversely affected
their QOL before LT.
Younossi,
20002
Measure HRQL
in patients
with chronic
CLD.
Determine
factors
associated
with more
severe
impairment.
Cross-
sectional
study
Patients with diagnosis
of
PBC or PSC.
Exclusion criteria: other
major active medical or
psychiatric disorder
requiring treatment;
malignancy; liver
transplantation; unable
to consent.
nZ 104 (75 PBC; 29 PSC)
Healthy
individuals
(nZ 52); same
period from
2 primary care
physicians at
Cleveland Clinic
Foundation.
Patients with
variety of
progressive
chronic
conditions.
SF-36, CLDQ
Patient’s
HRQL was
compared
with healthy
population,
patients
with
congestive
heart failure,
COPD and
diabetes.
PBC: For both SF-36 and
CLDQ, PBC patients had
greater HRQL impairment
compared to healthy
population. Increased
severity, increased
HRQL impairment (CLDQ
and PCS in SF-36; not MCS).
PSC: More HRQL impairment
than healthy population
(in all aspects). PSC did
not show gradual decline in
HRQL with disease severity.
PSC had less impairment
compared to other chronic
conditions.
No significant difference
between PSC and PBC HRQL.
Cholestatic patients had less
impairment in physical
health but more impairment
in mental health compared
to other chronic conditions.
Patients with pruritus had
more HRQL impairment.
Small sample size. Limit
ability to further describe
the relationship between
progression of CLD and
HRQL. (CLDQ shows no
difference on progression
and HRQL). Selection bias:
inclusion of more symptomatic
and advanced patients.
Marchesini,
20015
Study QOL
in patients
Cross-
sectional
Patients with
cirrhosis from
Normal
population
SF-36,
NHPQ
All domains of HRQL (except
pain) were altered in cirrhosis.
Bias when checking
questionnaires
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with cirrhosis
and factors
associated
with a poor
perceived
health status.
study 3 centers.
Exclusion
criteria: overt
encephalopathy,
preventing
correct filling
of questionnaires,
proven or
suspected
hepatocellular
carcinoma.
n Z 544
randomly
selected via
registry offices
(independent
of health
status).
Adjustment of
questionnaires
was made to
represent
normal Italian
population.
HRQL data
of patients
was compared
with age
and gender
adjusted
values of
2 random
samples of
Italian
population
(> 2000
participants).
In SF-36, all domains scored
significantly lower in cirrhosis.
Largest differences:
role-limitation physical,
general health, emotional.
Bodily pain was minimally
affected.
Same for NHP; largest
difference: energy, physical
mobility; pain no difference.
Younger patients (< 55 y)
showed more marked
impairment especially in
physical health, not in mental
health.
Muscle cramps were the factors
most closely associated with poor
health status perception.
Self-rating of disease
progression was associated with
ascites and pruritus.
and further instruction given to
complete missing items. Higher
rate of missing data was
expected and observed
(potential representative bias).
Unselected population,
comorbidities may lead to
poor perceived health status.
Poupon,
200412
Individualize
the impact
of PBC
on QOL.
Identify the
associations
between NHP
scores and
main
characteristic
of PBC.
Cross-
sectional
study
Unselected
patients with
PBC regardless
of the duration
or severity
of the disease.
Exclusion
criteria: presence
of associated
disorders
threatening
life expectancy,
previous liver
transplantation,
inclusion on
waiting list
for liver
transplantation.
n Z 276
Subjects
randomly
selected
from a large
prospective
cohort
(nZ 173),
in which only
workers
younger than
65 y were
included.
Volunteers
over age
65 y (nZ 103)
are either
nonaffected
relatives of
PBC patients
or relatives of
medical staff.
NHPQ PBC patients showed a strong
statistically significant
difference in worse scores for
energy and emotional reactions
compared to controls.
Social isolation was also affected
to a lesser extent.
A worse
overall QOL, expressed as the
percentage of positive answers,
was associated with pruritus,
jaundice, fatigue, splenomegaly,
and osteopenia.
Fatigue was the finding most
often associated with the
subscores dimensions.
There was no finding on impact
of pruritus on QOL but the
energy subscore was diminished
with pruritus
when the impact of pruritus
was tested independently
on each domain.
Clinical relevance of the results
of NHP could not be compared
with other generic QOL
instruments as SF-36 French
version was not available when
the study was done.
Some PBC and controls could
also have other comorbid
conditions such as diabetes,
arthritis, and heart diseases,
which may lead to poor
perceived health status.
(continued on next page)
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Table 2 (continued )
First
author,
yearref
Objective Study
design
Study population HRQL
measures
(method)
Summary
of findings
Study
limitationsIntervention
group
Comparison
group
Stanca,
20059
Examines the
extent of
fatigue and
its effect on
quality of
life in US PBC
patients.
Cross-
sectional
study
Patients with
antimitochondrial
antibody
positive PBC
were recruited
within the
Division of
Liver Diseases
at the Mount
Sinai School
of Medicine,
New York.
Exclusion
criteria: history
of ascites,
spontaneous
bacterial
peritonitis,
variceal
bleeding or
encephalopathy.
n Z 70
Nonliver
disease
controls
(nZ 21).
Women
aged 27e77 y.
NIDDK-QA From the 70 patients, fatigue
was reported by 50 patients,
depression by 34 and
pruritus by 31.
FIS and QOL scores in those
with or without fatigue and
depression significant
difference, but not in those
with or without pruritus.
Neither FIS nor QOL
scores correlate with age.
Not mentioned.
Benito de
Valle,
201210
Evaluate HRQL
and its
potential
determinants
in 2
population-
based cohorts
of patients
with PSC.
Study the
prevalence of
fatigue among
these patients.
Cohort
study
All patients
with PSC
residing in
Vastra Gotaland,
Sweden and
in Oxfordshire,
England.
Exclusion
criteria: patients
whose
permanent
address was
not within
the chosen
places, unable
to understand
Swedish
General
population
SF-36, CLDQ PSC patients had significant
lower scores in all SF-36 domains,
except the physical functioning
and bodily pain.
Patients who underwent liver
transplant showed no difference
to controls, except general
health.
Age showed negative impact on
SF-36 PCS; positive impact on
MCS.
Serum
alkaline phosphatase showed
negative impacts in all SF-36
domains.
Large duct PSC showed lower
SF-36 vitality and MCS.
Clinical data were obtained
retrospectively after
scrutinizing medical
records. Previous studies have
reported impaired quality of
life among patients with
IBD. 79% of PSC patients
had concomitant IBD in this
cohort. Possibility of IBD
confounding the results
cannot be excluded.
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and English.
n Z 182
CLDQ appeared similar to
SF-36.
Fatigue and psychological
distress showed no difference
between patients and controls.
Pruritus was identified as an
independent predictor of
SF-36 bodily pain and role
functioning domains.
General systemic symptoms
and pruritus are more related to
reduction of HRQL compared
to disease severity.
Gotthardt,
201413
Identify
factors
associated with
QOL in patients
with PSC.
Cross-
sectional
study
Patients with
confirmed
PSC treated
in endoscopy
facility/unit/
department
at University
Hospital of
Heidelberg,
Germany
during
2008e2009
were recruited.
Exclusion
criteria:
Patients who
had undergone
liver
transplantation.
n Z 113
Not
mentioned.
SF-36 Older age was associated with
reduced physical function
in SF-36.
Women appeared to have
lower score for all items in SF-36
compared to men, where
statistically significant
differences
were observed
in physical function and role
limitations because of emotional
problems.
QOL
decreased with increased pruritus
intensity in terms of physical and
social functioning, general and
mental health, bodily pain,
vitality, and roles.
Patients with pruritus also
had significantly higher PHQ-9
(depression) scores depending
on severity.
Method for patient
selection was not
clear as there was
no description
regarding exclusion
criteria and missing
patients. Patients with
other severe comorbidities
may lead to more
impaired QOL.
There was no
comparison
group established
in this study.
Raszeja-
Wyszomirska,
201511
Evaluate the
applicability
of PBC-40
and PBC-27
to PSC patients
for HRQL
assessment
by comparing
to generic
Cross-
sectional
study
Caucasians with
PSC who
received their
medical care
in this institution.
Mean age:
36  12 y.
Exclusion
criteria: other
53 matched
healthy
controls
SF-36,
PBC-40,
PBC-27
SF-36: Most SF-36 domains were
significantly lower in PSCs than
controls. Physical Functioning
and Mental Component Summary
scores were significantly
lower in female patients and
correlated negatively with age
but not with concurrent
inflammatory bowel disease.
Not mentioned.
(continued on next page)
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Table 2 (continued )
First
author,
yearref
Objective Study
design
Study population HRQL
measures
(method)
Summary
of findings
Study
limitationsIntervention
group
Comparison
group
SF-36.
To
systematically
evaluate the
impact of PSC
on patients’
HRQL.
severe
comorbidities
which could
influence HRQL
such as malignancy,
decompensated
diabetes mellitus,
renal impairment
(dialysis),
heart
failure 
NYHA II,
rheumatoid
arthritis or
pulmonary
disease.
n Z 102
(73 males;
29 females)
Cirrhosis was associated
with lower Physical Functioning,
Role Physical, General Health,
Vitality and Physical Component
Summary.
PBC-40 and PBC-27: Both tools
showed similar HRQL impairment
scoring. Fatigue and cognitive
were impaired in female
patients. Several correlations
existed between HRQL and
laboratory parameters, including
cholestatic tests and itch.
Cirrhosis correlated with Other
symptoms and Fatigue PBC-40.
PBC-40 vs. PBC-27: Strong
correlations among most
domains of both questionnaires
were seen, as well as between
SF-36 and PBC-40 or SF-36 and
PBC-27.
CLD Z cholestatic liver disease; CLDQZ Chronic Liver Disease Questionnaire; COPD Z chronic obstructive pulmonary disease; FISZ Fisk Fatigue Impact score; HRQL Z health-related
quality of life; HRQLZ health-related quality of life; IBDZ inflammatory bowel disease; LTZ liver transplant; MCSZ mental component summary; NHPQZ Nottingham Health Profile
Questionnaires; NIDDK LTD-QOL / NIDDK-QA Z National Institute of Diabetes and Digestive and Kidney Disease Liver Transplant Database e Quality of Life: Adults; NYHA IIZ New York
Heart Association class II; PBC Z primary biliary cirrhosis; PBC-27 Z primary biliary cirrhosis-27; PBC-40 Z primary biliary cirrhosis-40; PCS Z physical component summary; PHQ-
9 Z patient health questionnaire; PSC Z primary sclerosing cholangitis; QOL Z quality of life; SF-36 Z Short Form-36.
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from baseline HRQL. Two studies showed that there was no
significant difference in HRQL between PSC and PBC pa-
tients.2,8 Four studies also showed that HRQL among pa-
tients with CLD were further affected by worsening disease
severity.2,5,10,11Incidence and severity of pruritus among
cholestatic patients
Five of the studies2,5,9,10,12 revealed the number of pa-
tients who disclosed pruritus as one of the disease char-
acteristics of CLD. There were 336 out of 1153 (29%)
patients with CLD found to have pruritus in the five
studies.2,5,9,10,12 Two studies showed that HRQL impair-
ment was greater in patients with pruritus compared to
patients without pruritus.2,13 Five studies reported that
patients with pruritus had significant association with some
domains in different HRQL assessment tools used in the
studies.5,10e13Table 3 HRQL instruments used in eligible studies.
Instrument Type Goals
National Institute of
Diabetes and
Digestive and
Kidney Diseases-Quality
of Life: Adults
(NIDDK-QA)
Liver
disease-specific
Assess the impa
of liver disease
quality of life fr
the patients’ pe
Short Form-36 (SF-36) Generic Assess health fu
often used as a
general measure
of HRQL
Chronic Liver Disease
Questionnaire (CLDQ)
Liver
disease-specific
Assess the HRQL
of patients with
liver diseases.
Nottingham Health
Profile
Questionnaire (NHPQ)
Generic Measure patient
perceived emot
social and physi
health problems
(present distres
Primary Biliary
Cirrhosis-40 (PBC-40)
Primary biliary
cirrhosis-specific
Assess the impa
of PBC on patie
well being
Primary Biliary
Cirrhosis-27 (PBC-27)
Primary biliary
cirrhosis-specific
Simplified versio
of PBC-40. Asse
the impact of P
on patient’s weQuality assessment
In terms of study quality, only one study was rated as good
quality and the remaining seven studies were rated as
fair,2,5,8e13 although they met either nine or 10 quality
criteria. This indicates that they were close to good quality.
Overall, the quality of the findings that contributed to this
study is fair (Table 4).
Discussion
This is the first systematic review to assess the impact of
pruritus on HRQL among patients with CLD. Although pru-
ritus is a frequent symptom in liver disease, surprisingly few
studies have investigated the incidence and severity of
pruritus in CLD, as well as the impact of pruritus on HRQL
among the patients. HRQL assessment tools used to assess
the impact of pruritus also lack uniformity and
transparency.
The findings of this review suggest that the frequency of
pruritus is high among the patients with CLD. Although theDomains/subscales
ct
on
om
rspective.
4 domains: liver disease
symptoms, physical functioning,
health satisfaction and
overall well-being.16
nctioning; 8 subscales: physical functioning,
vitality, social functioning,
general health, bodily pain,
physical role, emotional role
and mental health.
2 component summary scales:
physical and mental component
summary scales (PCS and MCS).13,15
6 domains: fatigue, emotional
function, worry, activity,
abdominal symptoms and systemic symptoms.17
s’
ional,
cal
s).
Part I: 6 domains including
energy, sleep, pain, emotional
reactions, social isolation,
physical mobility.
Part II: effects of disease on
relevant daily activities:
occupation, jobs around the
home, social life, home life,
sex life, hobbies and holidays.18
ct
nt’s
6 domains: cognitive, itch,
fatigue, social, emotional and
other symptoms (5-point scale).19
n
ss
BC
ll being
7 domains: symptoms, dryness,
itch, fatigue, cognitive,
emotional and social.20
Table 4 Quality assessment for included studies by using quality assessment tool devised by National Institute of Health (NIH).
Criteria Studies (first author, yearref)
Gross,
19998
Younossi,
20002
Marchesini,
20015
Poupon,
200412
Stanca,
20059
Benito de
Valle, 201210
Gotthardt,
201413
Raszeja-
Wyszomirska,
201511
1. Was the research
question or
objective in this
paper clearly
stated?
U U U U U U U U
2. Was the study
population clearly
specified and
defined?
U ✗ (location
not
reported)
✗ (location
not
reported)
✗ (location
and time
period not
reported)
✗ (time
period not
reported)
U U ✗ (time period
not reported)
3. Was the
participation rate
of eligible persons
at least 50%?
U NR U NR NR ✗ U NR
4. Were all the
participants
selected or
recruited from the
same or similar
populations
(including the
same time
period)? Were
inclusion and
exclusion criteria
for being in the
study pre-
specified and
applied uniformly
to all participants?
U U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
5. Was a sample size
justification,
power
description, or
variance and
effect estimates
provided?
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
6. For the analyses in
this paper, were
the exposure(s) of
interest measured
prior to the
outcome(s) being
measured?
U U U U U U U U
7. Was the timeframe
sufficient so that
one could
reasonably expect
to see an
association
between exposure
and outcome if it
existed?
U ✗ ✗ ✗ ✗ ✗ ✗ ✗
698 X.Y. Jin, T.M. Khan
Table 4 (continued )
Criteria Studies (first author, yearref)
Gross,
19998
Younossi,
20002
Marchesini,
20015
Poupon,
200412
Stanca,
20059
Benito de
Valle, 201210
Gotthardt,
201413
Raszeja-
Wyszomirska,
201511
8. For exposures that
can vary in
amount or level,
did the study
examine different
levels of the
exposure as
related to the
outcome (e.g.,
categories of
exposure, or
exposure
measured as
continuous
variable)?
NA NA NA NA NA NA NA NA
9. Were the exposure
measures
(independent
variables) clearly
defined, valid,
reliable, and
implemented
consistently
across all study
participants?
U U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
U (for
intervention
group only)
10. Was the
exposure(s)
assessed more
than once over
time?
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
11. Were the
outcome
measures
(dependent
variables) clearly
defined, valid,
reliable, and
implemented
consistently
across all study
participants?
U U U U U U U U
12. Were the
outcome assessors
blinded to the
exposure status of
participants?
NA NA NA NA NA NA NA NA
13. Was loss to
follow-up after
baseline 20% or
less?
✗
(73%)
NA NA NA NA NA NA NA
14. Were key
potential
confounding
variables
U U U U U U U U
(continued on next page)
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Table 4 (continued )
Criteria Studies (first author, yearref)
Gross,
19998
Younossi,
20002
Marchesini,
20015
Poupon,
200412
Stanca,
20059
Benito de
Valle, 201210
Gotthardt,
201413
Raszeja-
Wyszomirska,
201511
measured and
adjusted
statistically for
their impact on
the relationship
between
exposure(s) and
outcome(s)?
Quality rating (good,
fair, poor)
Good Fair Fair Fair Fair Fair Fair Fair
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the impacts of pruritus on HRQL among the patients cannot
be neglected. Gross et al stated that pruritus was one of
the most bothersome symptoms experienced by patients
with CLD before liver transplantation.8 This may imply that
patients with CLD often experience skin itching to a degree
that it has critically affect their daily lives. Relatively few
studies have investigated the incidence of pruritus as the
reviewed studies focused mainly on HRQL among patients
with CLD. Thus, the incidence of pruritus among the pa-
tients may be underestimated from the results observed.
Greater HRQL impairment was found with increased
severity of pruritus among patients with CLD. Younossi
et al2 and Gotthardt et al13 were the only studies that
assessed the relationship between severity of pruritus and
HRQL among patients with CLD. Patients with CLD were
classified into four subgroups: no pruritus (), mild pruritus
(þ), moderate pruritus (þþ) and severe pruritus (þþþ).
Result had shown that HRQL impairment was greater in
patients with pruritus compared to patients without pruri-
tus. All the domains in both SF-36 and CLDQ declined with
increased severity of pruritus. Rishe et al,21 a study that
was not included in the review, found that “itch was
described as a sensation of bugs crawling and a deep itch,
which, at times, was relentless and made those with this
sensation want to tear their skin off or scratch until they
bled.” This suggests that patients with CLD perceive pru-
ritus as a severe and irritating symptom. The reasons for
not including Rishe et al were that it is a clinical report and
it does not utilize any validated QOL assessment tool to
measure HRQL of the patients. However, the questionnaires
generated by the author allowed PBC patients to describe
their experiences of living with itch. This study was able to
reflect the true feeling of patients on how they perceived
itch in their lives as well as support the findings of this
review.21
In terms of the impact of pruritus on HRQL, several
studies have shown that pruritus is significantly correlates
with certain domains in different QOL instruments. In
Marchesini et al,5 patients with pruritus were found to have
significant association with role limitationephysical, bodily
pain, general health, vitality, and role limitationeemo-
tional domains in SF-36. However, significant associationbetween pruritus and NHPQ domains were shown in energy,
sleep, and physical mobility subscores.5 In Benito De Valle
et al, pruritus was identified as an independent predictor of
SF-36 bodily pain and role functioning domains.10 Raszeja-
Wyszomirska et al also reported that itch domains in PBC-
40 and PBC-27 significantly correlate with vitality, social
functioning, and role limitationeemotional domains in SF-
36.11 In Gotthardt et al, the presence of pruritus was
significantly associated with several domains in SF-36 such
as impairment in physical functioning, general health, vi-
tality, mental health, bodily pain, and role limitations
because of physical health.13 Patients with pruritus also had
significantly higher PHQ-9 scores, indicating that degree of
depression increased with increased pruritus intensity or
frequency.13 There was no significant impact of pruritus on
HRQL found by Poupon et al,12 who, nevertheless, found
that the energy subscore in NHPQ was significantly dimin-
ished by the presence of pruritus when each domain was
independently tested.12 Stanca et al is the only study that
showed no significant difference of HRQL between patients
with pruritus and patients without pruritus.9 This may be
due to small sample size which is unable to detect the
significant effects of pruritus on HRQL; further, data were
not shown in the study.9 To summarize, pruritus was
described as an independent predictor of impaired HRQL in
patients with CLD, as well as a more important de-
terminants of HRQL than markers of liver disease
severity.2,5,10,13 Pruritus also appears to have substantial
impact on patients’ physical health (role limi-
tationephysical, physical mobility, energy), vitality, body
pain, and mental health (role limitationeemotional).
Other than CLDs, high incidence of pruritus is also seen
in other diseases such as hematologic disease, end-stage
renal disease and HIV.22e24 Studies have found that sys-
temic etiology was observed in 30% to 40% of patients with
pruritus and absence of itching dermatosis.25e27 Although
frequency of pruritus in patients with CLD is lower than
other systemic disease, not unexpectedly, presence of
pruritus has made the HRQL worse, regardless of any un-
derlying systemic disease the patient may have. Moreover,
the results of Kini et al show that there is no significant
difference between the impact of pruritus and chronic pain
on HRQL.28 Unlike pruritus, chronic pain is a famous topic
QOL in cholestatic liver disease-induced pruritus 701among healthcare researchers that has been well studied
consistently for centuries. The findings from Kini et al
support that pruritus has a great impact on patients’ QOL,
given that the extent of the QOL impacts of chronic pain
and pruritus are the same.28 Therefore, pruritus should be
deemed equally important as pain in order to obtain better
understanding in terms of disease complexity and devel-
opment of novel treatments through conducting more
research.
In contrast to CLD, higher incidence and prevalence of
pruritus were found in dermatological conditions such as
psoriasis and atopic dermatitis.29e32 Undeniably, there is
more research into the impact of pruritus on HRQL among
patients with dermatological diseases compared to sys-
temic diseases. Impact of pruritus was found to be more
pronounced among patients with skin disease as most of the
studies utilized skin-specific instruments to assess patients’
HRQL.29e32 Skin-specific instruments provide more
comprehensive assessment of characteristics and severity
of pruritus among the patients compared to generic in-
struments.4 In psoriasis patients, pruritus intensity was
found to have significant correlations with patients’ QOL,
feeling of stigmatization, mental distress and depressive
symptoms.30,31,33 Moreover, pruritus also showed negative
impacts on mood, concentration, work ability, sleep, and
appetite.29,31,34 Results regarding the impact of pruritus on
QOL among patients with psoriasis are similar to the results
of the review, especially in terms of mental health
impairment (role limitationeemotional domains in SF-36).
Among these, stigmatization plays a very important role
in affecting emotional wellness of patients. Generally, so-
cial stigma is not common in pruritus, as pruritus is a sub-
jective invisible sensation. Increases in stigmatization may
be explained by scratching behavior induced by itching
which will then draw attention from other people.31,35 Pa-
tients’ feelings of shame and guilt increase when they are
constantly stared at by other people.35 Excessive scratching
may also lead to unpleasant skin appearance such as
bleeding and excoriations, which results in increased stig-
matization, as well as increased risk of infection.35
Increased stigmatization will compromise patients’ self-
esteem, which in turns lead to poor working performance,
social withdrawal behavior, and interpersonal relationship
impairment. Altunay et al also found that pruritus had
comparable negative effects with psoriasis on HRQL.35 This
shows that pruritus is capable of inducing both self-stigma
and social stigma, even though it is not a visible skin con-
dition. However, treatment options for pruritus appeared
to be lack of consistency and effectivity.21,35 According to
the participants in Rishe et al’s study, their physicians did
not commence any treatments or management for their
itch even though they reported that the itch was very
troublesome.21 Thus, it is ultimately important to arouse
awareness among physicians and researchers in order to
formulate consistent and effective therapeutic guidelines
for pruritus management.
Several limitations must be considered. This review may
have missed some relevant papers published in non-English
journals. The overall level of evidence among the included
studies is low.36 Only observational cohort and cross-
sectional studies were recruited in the review. Neverthe-
less, quality of every included study was assessed tominimize potential risk of bias. Besides, most of the studies
used very small sample sizes and none of the studies re-
ported effect sizes. Other unreported comorbidities and
life controversies in both patients and healthy population
may also lead to poor perceived health status, which in turn
exaggerates the impact of pruritus on HRQL. Furthermore,
data available from the included studies are limited. Data
regarding incidence of pruritus and correlation between
pruritus and HRQL were not documented well in several
studies as most focused mainly on HRQL of patients with
CLD. Moreover, all the eight studies used different tools to
assess the QOL among the selected patients. Therefore, it
will be challenging to quantify the overall effect of pruritus
on QOL due to heterogenicity among the results. Therefore,
to avoid the chance of heterogenicity, the results are only
summarized and no quantitative analysis is performed.
Future research is encouraged to focus on assessing
impact of pruritus on HRQL and epidemiology of pruritus
among patients with CLD. To measure HRQL of the patients,
skin-specific instruments, such as Dermatology Life Quality
Index and Skindex, can be used in order to study the
characteristics and severity of pruritus extensively.37e39
Development of more transparent and consistent pruritus-
specific instruments for HRQL measures would also appear
as a useful area for upcoming research. Studies with larger
scales and sample sizes regarding impact of pruritus on
HRQL among patients with CLD alongside with longitudinal
follow-up studies are required in order to support the
existing data further.Conclusion
In conclusion, HRQL among patients with CLD is significantly
impaired by pruritus. Pruritus is a common chronic condi-
tion that was found in 29% of patients with CLD. Although
pruritus was found to be less common among patients with
CLD, data available on assessing the prevalence of pruritus
were scarce and insufficient. Thus, more high-quality
research and studies are required to provide more reli-
able data regarding the burden of pruritus among patients
with CLD. Among healthcare providers, pruritus should be
treated as important as the other symptoms in chronic liver
diseases as it can also be a sole indication for end-stage
liver disease.2,40 Physicians should also be more aware of
pruritic symptoms when treating patients with CLD as
scratching may impair patients’ QOL and lead to other
medical complications such as secondary infection.Acknowledgements
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